Share: Facebook Twitter LinkedIn
Activity Provided By:

i3 Health

Keeping Pace With Evolving Treatment Paradigms in Advanced Renal Cell Carcinoma: The Nurse’s View

Access Activity

Overview / Abstract:


Kidney cancer accounts for approximately 4% of all cancer diagnoses in the United States (ACS, 2020). An estimated 73,750 new cases are reported annually and 14,830 people die of the disease. Renal cell carcinoma, which comprises nearly 90% of all kidney cancers, is characterized by a lack of early warning signs, diverse clinical manifestations, and resistance to radiation and chemotherapy. Due to its often asymptomatic presentation, many patients have advanced disease at diagnosis, which is associated with poor outcomes. The 5-year survival rate for patients with regional RCC is only 70% and drops to a dismal 12% for those with distant metastases (ACS, 2020).


Oncology and urology nurses, nurse practitioners, clinical nurse specialists, and other health care professionals involved in the treatment of patients with RCC.


Upon completion of this activity, participants should be able to:

1.) Distinguish the mechanisms of action of IO agents and VEGFR TKIs in advanced RCC
2.) Differentiate the efficacy and safety profiles of IO and VEGFR TKI therapies for advanced RCC
3.) Assess strategies to improve treatment tolerability, control adverse events, and ensure the provision of patient-centered RCC care


Nov 29, 2021


Nurse Practitioner , Nursing CNE


Online, Webinar / Webcast / Video

Credits / Hours




Presenters / Authors / Faculty

Laura S. Wood, RN, MSN, OCN® (Chairperson)
Renal Cancer Research Coordinator
Cleveland Clinic Taussig Cancer Center

Nazy Zomorodian, RNC, MSN, CUNP, CCRC
Urology Nurse Practitioner
UCLA Medical Center

Virginia Seery, CRNP, MSN
Nurse Practitioner
Beth Israel Deaconess Medical Center

Colleen Lewis, NP
Director of Clinical Operations, Phase I Clinical Trials Program
Winship Cancer Institute

Activity Specialities / Related Topics

Nephrology, Oncology / Cancer / Radiation Therapy, Urology

Sponsors / Supporters / Grant Providers

This activity is supported by a medical educational grant from Exelixis, Inc. and independent educational grants from Eisai and Merck.

Keywords / Search Terms

i3 Health oncology, RCC, renal cell carcinoma, kidney cancer, CNE, NCPD, free CNE, free NCPD, ILNA points, free ILNA points, i3 Health, CE, free CE Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map